Pfiz­er in­vests in Ri­bon Ther­a­peu­tics; Ar­genx gets PDU­FA date ex­ten­sion

Mass­a­chu­setts-based biotech Ri­bon Ther­a­peu­tics has roped in a big name for some fi­nan­cial back­ing.

Ri­bon an­nounced on Mon­day that Pfiz­er has in­vest­ed $25 mil­lion in­to the biotech. Robert Rick­ert, Pfiz­er’s head of can­cer im­munol­o­gy dis­cov­ery, will be com­ing on­to Ri­bon’s sci­en­tif­ic ad­vi­so­ry board. The start­up will use the funds to sup­port the de­vel­op­ment of its pro­grams for on­col­o­gy and im­munol­o­gy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.